Clinical Trial

Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients

Study acronym: TORCH-met
Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Summary
1. Conduct a large-sample, multicenter, superiority, double-blind, randomized controlled clinical trial to verify the efficacy of TJC in reducing the risk of cardiovascular and cerebrovascular events in patients with metabolic syndrome at high cardiovascular and cerebrovascular risk (HCR-MS). 2. Further construct an evaluation system for the long-term cardiovascular and cerebrovascular benefits of traditional Chinese medicine in regulating glucose and lipid metabolism through the evaluative study of the cardiovascular and cerebrovascular benefits of TJC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-26; most recent amendment 2025-06-10.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-06-10
Trial Details
NCT Number NCT06908473
Lead Sponsor Guangdong Provincial Hospital of Traditional Chinese Medicine
Collaborators: TCM hospital of Sichuan Province, Xiyuan Hospital of CACMS, Shaanxi Provincial Hospital of Chinese Medicine, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Yinchuan Brain-Heart Simultaneous Treatment Internet Hospital Co., Ltd
Conditions Metabolic Syndrome, Cardiovascular Disease (CKD), Cerebrovascular Disease, Qi Deficiency and Blood Stasis
Enrollment 530 participants
Start Date 2025-04-24
Primary Completion 2028-07-31 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-13